Table 1 Baseline characteristics of participants
Characteristic | Q1 (n = 2823) | Q2 (n = 2821) | Q3 (n = 2830) | Q4 (n = 2810) | P-value |
|---|---|---|---|---|---|
FG/HDL-C ratio | 1.88 ± 0.33 | 2.78 ± 0.25 | 3.80 ± 0.37 | 6.52 ± 2.07 | < 0.001 |
Intervention | 1222 (43.29%) | 1436 (50.90%) | 1429 (50.49%) | 1405 (50.00%) | < 0.001 |
Sex | 0.006 | ||||
Female | 715 (25.33%) | 684 (24.25%) | 614 (21.70%) | 703 (25.02%) | |
Male | 2108 (74.67%) | 2137 (75.75%) | 2216 (78.30%) | 2107 (74.98%) | |
Age (years) | 60.64 ± 12.63 | 60.40 ± 12.22 | 59.42 ± 11.81 | 59.97 ± 11.50 | < 0.001 |
Heart rate (BPM) | 78.71 ± 18.21 | 79.68 ± 19.40 | 80.10 ± 19.08 | 82.93 ± 20.46 | < 0.001 |
Weight (kg) | 62.31 ± 9.36 | 63.13 ± 9.71 | 64.16 ± 9.77 | 64.22 ± 9.59 | < 0.001 |
SBP (mmHg) | 138.49 ± 27.74 | 141.78 ± 28.71 | 140.78 ± 29.49 | 139.85 ± 29.92 | < 0.001 |
Hemoglobin (g/dL) | 13.17 ± 1.99 | 13.36 ± 1.97 | 13.47 ± 1.99 | 13.18 ± 2.09 | < 0.001 |
CK-MB (units/L) | 65.77 ± 83.07 | 71.26 ± 91.22 | 74.03 ± 93.68 | 64.66 ± 88.11 | 0.087 |
Troponin (ng/mL) | 8.80 ± 22.86 | 10.88 ± 24.20 | 11.55 ± 26.99 | 9.33 ± 22.56 | 0.471 |
sCr (units/L) | 1.16 ± 0.54 | 1.14 ± 0.54 | 1.17 ± 0.65 | 1.22 ± 0.74 | 0.020 |
HDL-C (mg/dL) | 49.53 ± 11.04 | 42.65 ± 8.48 | 39.06 ± 8.99 | 36.09 ± 9.11 | < 0.001 |
LDL-C (mg/dL) | 125.08 ± 37.83 | 125.05 ± 40.55 | 123.17 ± 40.63 | 118.47 ± 41.81 | < 0.001 |
TRIG (mg/dL) | 130.37 ± 60.91 | 129.67 ± 64.97 | 138.14 ± 71.63 | 153.52 ± 84.79 | < 0.001 |
FG (mg/dL) | 91.78 ± 20.83 | 118.36 ± 24.42 | 148.15 ± 36.61 | 230.90 ± 75.54 | < 0.001 |
Smoking or tobacco | 1156 (40.95%) | 860 (30.49%) | 855 (30.21%) | 709 (25.23%) | < 0.001 |
Hypertension | 1132 (40.10%) | 1249 (44.28%) | 1397 (49.36%) | 1424 (50.68%) | < 0.001 |
PAD | 18 (0.64%) | 31 (1.10%) | 26 (0.92%) | 44 (1.57%) | 0.006 |
Prior TIA or stroke | 78 (2.76%) | 66 (2.34%) | 53 (1.87%) | 79 (2.81%) | 0.079 |
Diabetes | 652 (23.10%) | 946 (33.53%) | 1556 (54.98%) | 2242 (79.79%) | < 0.001 |
STEMI | 1751 (62.03%) | 1884 (66.78%) | 1892 (66.86%) | 1841 (65.52%) | < 0.001 |
Heart failure | 181 (6.41%) | 261 (9.25%) | 289 (10.21%) | 309 (11.00%) | < 0.001 |
Cardiac shock | 49 (1.74%) | 38 (1.35%) | 60 (2.12%) | 95 (3.38%) | < 0.001 |
Cardiac arrest | 26 (0.92%) | 21 (0.74%) | 36 (1.27%) | 38 (1.35%) | 0.085 |
Killip class | < 0.001 | ||||
I | 2499 (88.52%) | 2456 (87.06%) | 2429 (85.83%) | 2324 (82.70%) | |
II | 86 (3.05%) | 157 (5.57%) | 164 (5.80%) | 184 (6.55%) | |
III | 155 (5.49%) | 168 (5.96%) | 190 (6.71%) | 244 (8.68%) | |
IV | 83 (2.94%) | 40 (1.42%) | 47 (1.66%) | 58 (2.06%) | |
LVEF category | < 0.001 | ||||
1 | 281 (9.95%) | 363 (12.87%) | 408 (14.42%) | 505 (17.97%) | |
2 | 2083 (73.79%) | 1996 (70.76%) | 1971 (69.65%) | 1908 (67.90%) | |
3 | 142 (5.03%) | 166 (5.88%) | 191 (6.75%) | 137 (4.88%) | |
4 | 317 (11.23%) | 296 (10.49%) | 260 (9.19%) | 260 (9.25%) | |
Symptom onset to arrival (min) | 809.61 ± 1263.34 | 763.32 ± 1269.04 | 773.15 ± 1272.50 | 783.14 ± 1292.02 | 0.573 |
Door to balloon (min) | 538.33 ± 1421.01 | 483.20 ± 1204.73 | 510.32 ± 1513.07 | 511.91 ± 1489.49 | 0.832 |
Angiography | 1313 (46.51%) | 1942 (68.84%) | 2067 (73.04%) | 1989 (70.78%) | < 0.001 |
PCI | 1000 (35.42%) | 1615 (57.25%) | 1735 (61.31%) | 1640 (58.36%) | < 0.001 |
CABG | 8 (0.28%) | 20 (0.71%) | 15 (0.53%) | 14 (0.50%) | 0.162 |
Aspirin | 2350 (97.31%) | 2595 (97.34%) | 2623 (97.73%) | 2529 (97.49%) | 0.060 |
Clopidogrel | 2046 (84.72%) | 2120 (79.52%) | 2072 (77.20%) | 2042 (78.72%) | < 0.001 |
Ticagrelor | 223 (9.23%) | 347 (13.02%) | 378 (14.08%) | 344 (13.26%) | < 0.001 |
Beta blocker | 1392 (57.64%) | 1600 (60.02%) | 1703 (63.45%) | 1607 (61.95%) | < 0.001 |
Warfarin | 30 (1.24%) | 48 (1.80%) | 66 (2.46%) | 50 (1.93%) | 0.059 |
ACEI | 769 (31.84%) | 963 (36.12%) | 962 (35.84%) | 873 (33.65%) | 0.001 |
ARB | 202 (8.36%) | 233 (8.74%) | 240 (8.94%) | 243 (9.37%) | 0.018 |
Statin | 2340 (96.89%) | 2557 (95.91%) | 2583 (96.24%) | 2513 (96.88%) | 0.222 |